RBC Capital Markets thinks CSL is a bargain at current levels. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool ...
CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...
Significant opportunities exist in expanding home and small business security systems, particularly in Europe, where penetration is lower. Growth is driven by interactive services, smart home ...
CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...
This ASX heavyweight has potential to deliver superior returns but is more volatile. CSL remains the crown jewel of the ASX healthcare sector. Its plasma therapies, vaccines, and biologics underpin a ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results